U.S. Biotech Stock News

Recent conflict near the Strait of Hormuz has lifted oil prices and crude tanker rates, putting DHT Holdings (DHT) in focus as it receives the fully funded VLCC newbuilding DHT Addax for the spot market. See our latest analysis for DHT Holdings. Despite a 1-day share price return of a 1.8% decline to US$18.63 and some cooling over the past week, DHT’s 30-day and 90-day share price returns of 25.3% and 49.3% respectively, together with a 1-year total shareholder return of 96.5% and 5-year...

Vail Resorts (MTN) has just posted its Q2 2026 numbers, reporting revenue of US$1,083.9 million and basic EPS of US$5.87, alongside trailing twelve month EPS of US$6.38 on revenue of US$2.9 billion. The company’s quarterly revenue moved from US$1,137.2 million and EPS of US$6.54 in Q2 2025 to US$1,083.9 million and EPS of US$5.87 in Q2 2026. The latest trailing figures are in focus for investors considering how earnings power holds up across seasons. With net profit margins easing over the...

Viasat’s recent performance snapshot Viasat (VSAT) has drawn fresh investor attention after recent trading, with the stock last closing at $46.31. The company operates in satellite broadband, in-flight connectivity, and government communications services. Over the past month, Viasat has delivered an 11.06% return, while the past 3 months show a 24.19% gain, and the 1 year total return is 279.9%. Year to date, the stock is up 23.07%. See our latest analysis for Viasat. Viasat’s recent share...

Why Axon Enterprise stock is in focus after new guidance and earnings Axon Enterprise (AXON) has drawn fresh attention after issuing full year 2026 revenue growth guidance of 27% to 30%, alongside reporting its fourth quarter and full year 2025 financial results. See our latest analysis for Axon Enterprise. The recent guidance and results arrived after a sharp run up, with a 30 day share price return of 27.95%, followed by a 1 day share price decline of 5.20% and a 7 day share price decline...

Amplify Energy FY 2025 Earnings Snapshot Amplify Energy (AMPY) closed out FY 2025 with Q4 revenue of about US$56.6 million and basic EPS of US$1.53, while trailing 12 month EPS sat at US$1.03 on net income of US$41.6 million and a net margin of 15.8% versus 4.2% the prior year, supported by a US$54.7 million one off gain. Over the last few quarters, revenue has moved from US$69.0 million in Q4 2024 to US$72.1 million in Q1 2025, US$68.4 million in Q2, US$66.4 million in Q3 and US$56.6 million...

COLORfest launch puts Sally Beauty Holdings (SBH) experiential retail in focus Sally Beauty Holdings (SBH) is rolling out COLORfest, a month-long hair and nail color campaign anchored by a free pop-up at The Grove in Los Angeles. The initiative highlights its push into immersive, education-led beauty retail. See our latest analysis for Sally Beauty Holdings. At a share price of US$15.03, Sally Beauty Holdings has had a mixed few months, with a 30 day share price return of 7% decline and a 90...

Apple is expanding iPhone manufacturing in India, now producing around a quarter of its global iPhone output in the country. The company has increased its India iPhone production by over 50% year on year as it reduces reliance on China. Apple is preparing to launch Apple Pay in India and is deepening local partnerships alongside a growing retail footprint. Apple (NasdaqGS:AAPL) is trading at $260.83, with a 1 year return of 18.6% and a 5 year return of 113.3%. These moves into India sit...

If you are wondering whether Autodesk's current share price actually reflects what the business is worth, you are not alone. This article is built to help you connect the dots between the stock and its underlying value. The stock recently closed at US$253.85, with returns of 0.2% over the last 7 days, 5.6% over the last 30 days, an 11.5% decline year to date, and 1.2% over the past year, which gives mixed signals about how the market is currently pricing the company. Recent coverage around...

Recent share performance and business snapshot Novo Nordisk (NVO) has had a mixed run recently, with the stock showing a 2.7% one day decline alongside gains over the past week but weaker returns over the past month and past 3 months. For longer term holders, the picture has also been challenging, with a 49.4% negative 1 year total return and a 43.8% negative 3 year total return, partly offset by a 13.3% positive 5 year total return. Against this share price backdrop, Novo Nordisk reports...

RideNow Group (NasdaqCM:RDNW) has released its FY 2025 numbers, reporting fourth quarter revenue of US$256.9 million and a basic EPS loss of US$0.17. Trailing 12 month revenue was about US$1.1 billion and EPS for the period was a loss of US$1.38. Over the past few quarters, revenue has ranged from US$244.7 million to US$299.9 million per quarter, while quarterly EPS losses have been between US$0.11 and US$0.85. This gives investors a clear view of a business that is generating meaningful...

Fluent (FLNT) just wrapped up FY 2025 with Q4 revenue of US$61.8 million and a basic EPS loss of US$0.13, alongside net income excluding extra items of a US$4.1 million loss. This puts the focus firmly on how efficiently it is turning sales into profits. The company has seen quarterly revenue move from US$65.4 million in Q4 2024 to US$61.8 million in Q4 2025, while basic EPS shifted from a US$0.19 loss to a US$0.13 loss over the same periods. This sets the backdrop for investors who are...

Fulton Financial (NasdaqGS:FULT) has announced the retirement of Chief Human Resources Officer Bernadette Taylor. Karen Grafje, an internal leader with extensive industry experience, has been promoted to Chief Human Resources Officer. The transition places Grafje in a key role overseeing talent, culture, and workforce initiatives across the company. For investors tracking Fulton Financial at a share price of $20.01, this leadership change follows a mixed stretch of recent stock performance...

Latest FY 2025 earnings snapshot Priority Technology Holdings (PRTH) has wrapped up FY 2025 with fourth quarter revenue of US$247.1 million and EPS of US$0.11, while trailing twelve month EPS sat at US$0.70 on revenue of US$953.0 million. Over recent periods the company has seen revenue move from US$227.1 million in Q4 2024 to US$247.1 million in Q4 2025, with quarterly EPS shifting from a loss of US$0.05 in Q4 2024 to a profit of US$0.11 in Q4 2025 and TTM EPS climbing from a loss of US$0.31...

NIO (NIO) has closed out FY 2025 with Q4 revenue of C¥34.7b and basic EPS of C¥0.05, alongside trailing twelve month revenue of C¥87.5b and a trailing basic EPS loss of C¥6.85. This puts a spotlight on how quickly the earnings line is moving relative to the top line. The company has seen quarterly revenue move from C¥19.7b and a basic EPS loss of C¥3.45 in Q4 2024 to C¥34.7b and basic EPS of C¥0.05 in Q4 2025. Over the same period, trailing twelve month revenue shifted from C¥65.7b with a...

Earnings and 2026 Guidance Put BeOne Medicines in Focus BeOne Medicines (ONC) is drawing attention after reporting fourth quarter and full year 2025 results that shifted from a prior net loss to a net profit, alongside new 2026 revenue and operating income guidance. See our latest analysis for BeOne Medicines. The latest earnings and 2026 guidance came after a choppy stretch for the stock, with a 1 month share price return of 13.71% decline but a 1 year total shareholder return of 24.29%,...

Apyx Medical (APYX) just closed out FY 2025 with fourth quarter revenue of US$19.2 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$1.3 million loss. Over the last six reported quarters in this dataset, the company has seen quarterly revenue range from US$9.4 million to US$19.2 million, while basic EPS moved between a loss of US$0.14 and a loss of US$0.03, and trailing twelve month revenue most recently sat at US$52.8 million against an annual net...

ADC Therapeutics (ADCT) closed out FY 2025 with Q4 revenue of US$23.1 million and a basic EPS loss of US$0.04, alongside net income excluding extra items of a US$6.4 million loss. The company has seen quarterly revenue move from US$16.9 million in Q4 2024 to US$23.1 million in Q4 2025, while basic EPS losses shifted from US$0.29 to US$0.04 over the same period. This sets the stage for investors to focus on how these headline figures translate into the quality and direction of margins. See our...

If you are wondering whether Gartner's current share price still matches its underlying worth, you are not alone. This article focuses squarely on what you might be paying for versus what you are getting. The stock last closed at US$159.06, with returns of a 3.5% decline over 7 days, 1.7% over 30 days, a 32.9% decline year to date and a 65.9% decline over 1 year, while the 3 year and 5 year returns show a 50.3% decline and a 15.1% decline respectively. These moves have put valuation...

Recent share performance and what it might mean for investors Alaska Air Group (ALK) has seen its share price move sharply in recent periods, with a 27.2% decline over the past month and a 12.7% decline over the past 3 months catching investor attention. See our latest analysis for Alaska Air Group. Looking beyond the recent pullback, Alaska Air Group’s 1 day share price return of 2.27% contrasts with weaker momentum over the past month and year to date. The 1 year total shareholder return of...

In late February 2026, American Healthcare REIT, Inc. completed an at-the-market follow-on equity offering raising about US$769.86 million across multiple common stock tranches and reported fourth-quarter 2025 results showing revenue of US$604.08 million and net income of US$10.78 million. The company also issued 2026 guidance calling for higher net income and same-store net operating income growth, while quarterly real estate impairment charges fell sharply year-on-year to US$11.80 million,...

In its latest quarterly update, Brown & Brown reported revenue and organic revenue below analyst expectations, even as it delivered some of the fastest revenue growth among insurance brokerage peers, underscoring a contrast between strong top-line expansion and the market’s higher bar for performance. This gap between rapid industry-relative growth and unmet consensus forecasts highlights how closely Brown & Brown is now being measured against increasingly ambitious expectations for its...

In recent months, Glacier Bancorp reported softer quarterly results, with net interest income growth trailing the wider banking industry and earnings per share falling even as revenue increased. This divergence between rising revenue and declining per-share earnings has raised questions about the bank’s efficiency, cost structure, and overall profitability quality. With concerns mounting over weaker quarterly performance and profitability trends, we’ll now examine how this development...

Johnson & Johnson (JNJ) just secured U.S. FDA approval for TECVAYLI plus DARZALEX FASPRO in adults with relapsed or refractory multiple myeloma after at least one prior therapy, reshaping attention on the stock’s drug pipeline. See our latest analysis for Johnson & Johnson. The FDA approval comes after a run of pipeline updates in oncology and autoimmune diseases, while Johnson & Johnson also faces ongoing talc and antitrust litigation in North America that keeps legal risk in focus alongside...

National Presto Industries, Inc. has affirmed an annual cash dividend of US$1.00 per share, with an ex-dividend and record date of March 9, 2026, and payment scheduled for March 20, 2026. The dividend decision comes after the company reported very strong 2025 net sales growth driven by fulfilling a sizable Defense segment backlog, while its Housewares/Small Appliance business contended with tariff-related pressures on demand and costs. Next, we’ll examine how the Defense segment’s...